OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 11:36:54 2024-07-03 EDT | ||
| 1.17 EUR | -7.87% |
|
| Current month | -1.55% | ||
| 1 month | +13.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 1.17 | -7.87% |
| 24-07-02 | 1.27 | -3.79% |
| 24-07-01 | 1.32 | +2.33% |
| 24-06-28 | 1.29 | -1.53% |
| 24-06-27 | 1.31 | +0.77% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 11:36 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | HG8WCY |
| ISIN | DE000HG8WCY7 |
| Date issued | 2023-03-20 |
| Strike | 75.03 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 0.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.37 € |
|---|---|
| Lowest since issue | 0.06 € |
| Spread | 0.01 € |
| Spread % | 0.84% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
